Malvern-based Endo has agreed to merge with Mallinckrodt in a cash and stock deal, valuing the combined pharmaceutical ...

Talos Energy's solid acquisition strategy, strong debt repayment, and management evaluation are key for reducing investment ...

Mallinckrodt and Endo are merging in a $6.7 billion deal, with a pro forma NYSE listing and $900 million in financing.

Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York Stock Exchange, the two drugmakers said Thursday.

The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic ...

Mallinckrodt and Endo, drugmakers with a shared history of bankruptcy and U.S. opioid litigation, will merge in a deal valued ...

The new entity will be listed on the New York Stock Exchange and is expected to generate pro forma revenue of $3.6 billion in ...

Mallinckrodt Pharmaceuticals and Endo Inc. plan to merge and create a $6.7 billion company in a move that will cut costs and broaden access to patients and new treatments.

The C$15 billion Whitecap-Veren merger creates the 7th-largest Canadian oil & gas producer. Read why SPGYF and VRN stocks are ...

Veren and Whitecap Resources Inc. have merged in a C$15 billion deal, creating the largest Canadian light oil producer with strong financial outlook and potential for growth.

We recently published a list of 12 Stocks with Heavy Insider Buying in 2025. In this article, we are going to take a look at ...

Despite his reputation as a long-term investor, Buffett has engaged in merger arbitrages for more than 30 years, including ...